You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Claims for Patent: 7,312,237

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,312,237

Title:	Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
Abstract:	Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Inventor(s):	Lee; Francis Y. F. (Yardley, PA)
Assignee:	Bristol-Myers Squibb Co. (Princeton, NJ)
Application Number:	10/091,061
Patent Claims:	1. A method of treating cancer in a mammal selected from metastatic breast cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, colon cancer, and/or small cell lung cancer, comprising administering to the mammal a therapeutically-effective combination of (1) a dosage unit of capecitabine and (2) a dosage unit of Compound (1), having the formula, ##STR00020## or a pharmaceutically-acceptable hydrate, solvate, or geometric, optical, or stereoisomer of Compound (1), wherein the administration will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of capecitabine or the dosage unit of Compound (1) alone. 2. The method of claim 1 wherein the cancer is metastatic breast cancer refractory to taxane treatment. 3. The method of claim 1 wherein the cancer is metastatic breast cancer resistant to taxane treatment. 4. The method of claim 1 wherein the cancer is metastatic breast cancer sensitive to taxane treatment. 5. The method according to claim 1, wherein the capecitabine is administered following the administration of Compound 1. 6. The method according to claim 1, wherein the capecitabine is administered before the administration of Compound 1. 7. The method according to claim 1, wherein the capecitabine is administered substantially simultaneously with the administration of Compound 1. 8. The method according to claim 1, wherein the capecitabine is administered orally and the Compound 1 is administered parenterally. 9. The method according to claim 1, wherein the capecitabine is administered orally and the Compound 1 is administered orally. 10. A method of treating cancer in a mammal selected from metastatic breast cancer, lung cancer, pancreatic cancer, ovarian cancer, prostate cancer, colon cancer, and/or small cell lung cancer, comprising administering to the mammal a synergistically-effective combination of capecitabine and Compound (1), having the formula, ##STR00021## or a pharmaceutically-acceptable hydrate, solvate, or geometric, optical, or stereoisomer of Compound (1). 11. The method of claim 10, wherein the cancer is metastatic breast cancer. 12. The method of claim 10 wherein the cancer is refractory to taxane treatment. 13. The method of claim 10 wherein the cancer is resistant to taxane treatment. 14. The method of claim 10 wherein the cancer is sensitive to taxane treatment.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.